



Portfolio Media, Inc. | 230 Park Avenue, 7th Floor | New York, NY 10169 | www.law360.com
Phone: +1 646 783 7100 | Fax: +1 646 783 7161 | customerservice@law360.com


Morgan Lewis Boosts Life Sciences Team With Regulatory Pro

By **Max Austin**

Law360, London (October 20, 2025, 10:56 AM BST) -- Morgan Lewis has bolstered its life sciences capability with a regulatory veteran from Arnold & Porter as clients prepare for the European Union's regulatory overhaul of its medicines framework.

Jacqueline Mulryne, who has joined the London office of Morgan Lewis & Bockius LLP, spent more than two decades at Arnold & Porter Kaye Scholer LLP, where she was a partner. She took up her new position on Oct. 13.

Mulryne studied natural sciences at the University of Cambridge before beginning her legal career as a trainee solicitor at Arnold & Porter. Speaking to Law360 on Friday, she said she still considers herself a "scientist at heart," despite making the shift from science to law.



Jacqueline Mulryne

"It actually felt very natural for me," Mulryne said. "Despite my background in science, both fields rely on very similar skills — problem-solving, navigating a route through complex issues and providing clear advice and conclusions. I think they are more similar than people think."

Mulryne regularly advises clients in the pharmaceutical, medical technology, cosmetics and food sectors. She represents them before agencies including the European Medicines Agency and the Medicines and Healthcare Products Regulatory Agency in Britain.

Most of her work focuses on helping clients bring new products to market. This includes maximizing intellectual property rights and navigating exclusive market protections granted by regulators for clients. She also counsels on the classification of products, clinical research, winning approval and strategy for gaining market access.

Mulryne will work closely at Morgan Lewis with the firm's global life sciences and intellectual property teams. She follows the recent additions to the London office of **two IP partners** Tim Powell and Hiroshi Sheraton and Luciano Griebel, a mergers and acquisitions partner.

Mulryne said that companies should stay alert to shifting regulatory requirements, particularly after the EU rolled out its new rules on devices, designed to strengthen product safety and user oversight.

"Quite often, the laws and guidance don't fit neatly with new products, and I can help clients work their way through that," Mulryne said. "It's a bit like a puzzle for me — all these overlapping rules, the products, and the laws."

Mulryne added that the EU's ongoing overhaul of its medicines framework is increasing the regulatory pressure. The reform is designed to improve access to medicines and introduce new

rules governing medical devices, use of artificial intelligence, data sharing and biotechnology.

"It can be quite difficult for companies to know which rules apply to their product, especially when those products now combine multiple elements," she said. "You might have a medicine with a device component, an AI algorithm, and even an aspect of cell or gene therapy. These are incredible advances for patients, but they make the regulatory pathway much more complicated."

--Editing by Ed Harris.

All Content © 2003-2025, Portfolio Media, Inc.